Zura Bio appoints Muzammil Mustufa chief business officer

Zura Bio

Zura Bio

ZURA

0.00
  • Zura Bio named Muzammil Mustufa chief business officer, adding a new senior executive to lead corporate strategy, business development, commercial planning, investor relations.
  • Mustufa most recently served as vice president of corporate strategy at Amicus Therapeutics, where he worked on global launch and commercialization plans for two orphan-disease medicines.
  • He later led integration planning tied to BioMarin Pharmaceutical’s USD 4.8 billion acquisition of Amicus.
  • Earlier roles included positions at GSK, The Frankel Group, and The D.E. Shaw Group.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605130730BIZWIRE_USPR_____20260513_BW568466) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.